Entheon Biomedical Corp. Launches HaluGen s Psychedelics Genetic Test
HaluGen s DNA genetic testing provides insights into the sensitivity and risks associated with psychedelic-assisted psychotherapy
Vancouver, British Columbia (Newsfile Corp. - April 6, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ( Entheon or the Company ), a biotechnology company focused on developing psychedelic medicines to treat addiction, announces the launch of the industry s first Psychedelics Genetic Test Kit, developed by wholly-owned subsidiary, HaluGen Life Sciences Inc. ( HaluGen ), and that it is now available for sale within Canada.
HaluGen s psychedelic pre-screening platform and DNA testing provides genetic, personal and familial insights to better inform one s psychedelic assisted therapy experience. By obtaining DNA test results, individuals and healthcare professionals are equipped with data to improve psychedelic assisted therapy patient care and reduce side effects and risk. Th
Entheon Biomedical Corp. Provides Update on Subsidiary, HaluGen Life Sciences
Vancouver, British Columbia (Newsfile Corp. - February 24, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) (
Entheon or the
Company ), a biotechnology company focused on developing psychedelic medicines to treat addiction, provides a production update on HaluGen Life Sciences Inc. (
HaluGen ), a wholly-owned subsidiary of Entheon, which is in the business of developing and commercializing a genetic test designed to identify specific DNA biomarkers in order to gauge the risk and potential of adverse reactions toward hallucinogenic drugs.
Following the Company s announcement dated January 14, 2021, detailing Entheon s acquisition of HaluGen, the Company confirms that HaluGen s proprietary psychedelics genetic test kit and technology platform has completed research and development and is nearing commercial production.
JP Morgan Chase: 31,5 Millionen Dollar für Jamie Dimon faz.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from faz.net Daily Mail and Mail on Sunday newspapers.
Entheon Biomedical Corp. Announces Acquisition of HaluGen Life Sciences Inc.
Vancouver, British Columbia (Newsfile Corp. - January 14, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) (
Entheon or the
Company ) is pleased to announce that the Company completed its acquisition of HaluGen Life Sciences Inc. (
HaluGen ), a biotech company in the business of developing and commercializing a pre-screening test to identify genetic markers predictive of an individual s reaction to hallucinogenic drugs. The Company acquired 100% of the issued and outstanding common shares in the capital of HaluGen (the
HaluGen Shares ) from the shareholders of HaluGen (the
HaluGen Shareholders ) pursuant to a share exchange agreement among the Company, HaluGen and the HaluGen Shareholders, resulting in HaluGen becoming a wholly-owned subsidiary of Entheon (the
Halo Labs Completes Securities Issuance to Independent Consultants, Related Parties, and Suppliers
News provided by
Share this article
/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICERS OR FOR DISSEMINATION IN THE UNITED STATES./
TORONTO, Dec. 22, 2020 /CNW/ - Halo Labs Inc. ( Halo or the Company ) (NEO: HALO) (OTCQX: AGEEF) (Germany: A9KN) today announces that is has completed the issuance of 28,227,881 common shares of the Company (the Compensation Shares ) to certain independent consultants, related parties, and suppliers of the Company, in satisfaction of approximately C$2,142,241.90 in fees, payables, and other compensation accrued between April 2020 and August 2020.
The Company has also issued an aggregate of 18,000,000 warrants ( Compensation Warrants ) to independent consultants of the Company. The Compensation Warrants have an exercise price of $0.05 and expire one year from the date of issuance.